Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In hamster adipocyte ghosts, the influence of the antilipolytic agents, nicotinic acid, 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) and various related compounds, was studied on
adenylate cyclase
and low Km GTPase activities. As shown before for hormonal factors and nicotinic acid, the new drug, acipimox, inhibited
adenylate cyclase
by a GTP-dependent process, which was amplified by sodium ions; half-maximal inhibition occurred at about 10 mumol/l acipimox. For the various compounds studied, the following rank order of potency in inhibition of
adenylate cyclase
was obtained, nicotinic acid greater than 3-carboxy-5-methylpyrazole greater than acipimox greater than 3-carboxy-5-methylisoxazole;
6-hydroxynicotinic acid
and beta-pyridylcarbinol had no effect up to 300 mumol/l. In the same membrane system the antilipolytic drugs increased GTP hydrolysis by stimulation of a low Km GTPase as shown before for antilipolytic hormones. The potency order of the antilipolytic agents studied was identical for GTPase stimulation and
adenylate cyclase
inhibition. The data suggest that the antilipolytic drugs studied act on adipocyte
adenylate cyclase
via membrane-bound receptors in a hormone-like manner and that stimulation of a high affinity GTPase is involved in the mechanism of
adenylate cyclase
inhibition by these agents.
...
PMID:Inhibition of adenylate cyclase and stimulation of a high affinity GTPase by the antilipolytic agents, nicotinic acid, acipimox and various related compounds. 614 Sep 25